Search Beyond News…

Obesity Action Coalition urges Starbucks to reverse planned withdrawal of GLP-1 obesity drug coverage for employees

Executive summary: The Obesity Action Coalition called on Starbucks to reverse its reported decision to end health‑plan coverage of GLP‑1 medications for obesity treatment, with the change expected to begin in October 2026. The decision influences employee access to a widely used obesity therapy, potentially affecting Starbucks’ health‑care costs, workforce productivity, and setting a precedent for other large employers evaluating GLP‑1 benefits.

Who is involved: Obesity Action Coalition, Starbucks corporate leadership, Starbucks employees eligible for the benefit, and health‑plan administrators.

Likely next: Starbucks is expected to announce a final decision on the GLP‑1 coverage policy by late September 2026, after which the OAC may escalate its campaign or seek dialogue with the company.

The Obesity Action Coalition (OAC) has publicly asked Starbucks to reconsider its reported plan to end health‑plan coverage of GLP‑1 medications prescribed for weight loss, a move slated to take effect in October 2026. The appeal highlights concerns that removing the benefit could limit employee access to effective obesity treatment and affect workplace health outcomes. While Starbucks has not confirmed the policy change, the OAC’s request adds pressure on the company to clarify its benefits strategy amid growing employer interest in GLP‑1 therapies.

Timeline

Analysis — what this means

Likely next events

Sectors affected

Regulatory implications

Key entities

Sources

Related cases

Browse the full archive →